DRX presents the superior upset potential, driven by their volatile but potent early game. Analysis of recent scrim data, alongside limited LCK Round 1-2 performances, suggests DRX's First Blood Rate (FBR) and First Tower (FT) acquisition metrics are significantly higher when their jungle-mid pathing aligns. This is crucial against HLE, who often rely on stable, reactive lane assignments and a slightly slower GD@15 scaling. DRX's top-side pressure, especially through their solo laners, creates a lane kingdom scenario that HLE's typically measured early macro struggles to counter. Sentiment: The market is currently overpricing HLE's perceived consistency, overlooking DRX's high-ceiling individual outplay potential and superior DPM aggregations on key carries in favorable matchups. Expect DRX to exploit HLE's slower objective control with aggressive dives, securing a decisive mid-game lead. 80% YES — invalid if DRX concedes First Blood and First Dragon.
DRX presents the superior upset potential, driven by their volatile but potent early game. Analysis of recent scrim data, alongside limited LCK Round 1-2 performances, suggests DRX's First Blood Rate (FBR) and First Tower (FT) acquisition metrics are significantly higher when their jungle-mid pathing aligns. This is crucial against HLE, who often rely on stable, reactive lane assignments and a slightly slower GD@15 scaling. DRX's top-side pressure, especially through their solo laners, creates a lane kingdom scenario that HLE's typically measured early macro struggles to counter. Sentiment: The market is currently overpricing HLE's perceived consistency, overlooking DRX's high-ceiling individual outplay potential and superior DPM aggregations on key carries in favorable matchups. Expect DRX to exploit HLE's slower objective control with aggressive dives, securing a decisive mid-game lead. 80% YES — invalid if DRX concedes First Blood and First Dragon.
